Bon Natural Life (BON) AI Stock Analysis

• Market Cap: $14.14M
• Dividend Yield: N/A
• Average Volume (3M): 2.24M
• Price to Earnings (P/E): 0.6
• Beta (1Y): 1.86
• Revenue Growth: -15.44%
• EPS Growth: -94.04%
• Country: US
• Employees: 97
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Packaged Foods
• EPS (TTM): N/A
• Shares Outstanding: 6,086,971
• 10 Day Avg. Volume: 115,576
• 30 Day Avg. Volume: 2,242,045
• PEG Ratio: -2.79
• Price to Book (P/B): 2.53
• Price to Sales (P/S): 4.65
• P/FCF Ratio: -14.36
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 0.69
• Enterprise Value/Gross Profit: 2.45
• Enterprise Value/Ebitda: 5.92
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $2.00 ▲(17.65% Upside)

Bon Natural Life's overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. While the stock appears undervalued based on its P/E ratio, significant financial and operational challenges overshadow this potential opportunity.

Positive Factors

Operational Efficiency

Improved operational efficiency indicates better cost management and resource utilization, enhancing long-term profitability and competitiveness.

Strategic Partnership

The partnership expands market reach in China, leveraging advanced technology to meet demand for health solutions, boosting revenue potential.

Low Leverage

Low leverage provides financial stability and flexibility, allowing the company to invest in growth opportunities without excessive debt burden.

Negative Factors

Revenue Decline

Declining revenue indicates challenges in market demand or competitive positioning, potentially impacting long-term growth and market share.

Negative Cash Flows

Strained liquidity from negative cash flows can limit operational flexibility and investment in growth, posing risks to financial health.

Declining Profit Margins

Pressure on profit margins suggests cost pressures or pricing challenges, which can erode profitability and competitive edge over time.

Bon Natural Life Business Overview & Revenue Model

Company Description

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.

How the Company Makes Money

Bon Natural Life generates revenue primarily through the sale of its dietary supplements and personal care products. The company utilizes a multi-channel distribution strategy, selling directly to consumers via its online platform as well as through retail partnerships with health food stores and wellness-focused retailers. Key revenue streams include product sales, subscription services for regular customers, and bulk orders from health professionals and wellness practitioners. Additionally, BON may engage in partnerships with other brands and influencers in the wellness space to enhance visibility and reach, further contributing to its earnings.

Bon Natural Life Financial Statement Overview

Summary

Bon Natural Life faces a challenging financial landscape with declining revenues and profitability, coupled with negative cash flows. Despite a strong equity position, operational and liquidity issues pose risks to future financial health.

Income Statement

The income statement shows a declining trend in revenue with a significant drop in net income over the past year. The gross profit margin for the latest annual period is approximately 29.8%, which is decent but overshadowed by the steep decline in both EBIT and net profit margins, indicating pressure on profitability. The revenue growth rate is negative, highlighting a challenging environment for revenue generation.

Balance Sheet

The balance sheet reflects a strong equity position with a debt-to-equity ratio of approximately 0.17, indicating low leverage. The return on equity (ROE) is around 0.9%, suggesting limited profitability relative to equity. The equity ratio stands at about 71.1%, showcasing strong financial stability, but the declining asset base and increasing liabilities are potential concerns.

Cash Flow

The cash flow statement is concerning, with negative operating and free cash flows, indicating strained liquidity. The operating cash flow to net income ratio is negative, pointing to operational challenges in generating cash relative to reported income. The free cash flow growth rate is also negative, highlighting deteriorating cash flow conditions.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.61M	23.84M	29.52M	29.91M	25.49M	18.22M
Gross Profit	6.05M	7.11M	8.84M	9.42M	7.11M	5.20M
EBITDA	2.50M	2.30M	6.98M	8.33M	6.13M	3.70M
Net Income	577.92K	398.17K	4.60M	6.24M	4.59M	3.03M
Balance Sheet
Total Assets	71.58M	61.77M	46.56M	37.26M	36.41M	25.20M
Cash, Cash Equivalents and Short-Term Investments	8.89M	80.47K	112.82K	840.86K	3.61M	53.11K
Total Debt	8.76M	7.30M	4.12M	5.41M	3.31M	5.72M
Total Liabilities	17.68M	17.42M	10.57M	7.16M	9.88M	14.18M
Stockholders Equity	53.52M	43.91M	35.48M	29.56M	26.01M	10.52M
Cash Flow
Free Cash Flow	-10.14M	-7.73M	-713.82K	-4.92M	-700.78K	-1.69M
Operating Cash Flow	-10.13M	-7.72M	-651.91K	-187.12K	4.05M	2.64M
Investing Cash Flow	-10.64K	-15.73K	-1.19M	-3.06M	-7.44M	-3.00M
Financing Cash Flow	18.57M	8.76M	1.16M	2.26M	5.35M	112.49K

Bon Natural Life Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BON, the sentiment is Neutral. The current price of 1.7 is above the 20-day moving average (MA) of 1.67, below the 50-day MA of 1.76, and above the 200-day MA of 1.65, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.92 is Neutral, neither overbought nor oversold. The STOCH value of 96.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BON.

Bon Natural Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
BON	52 Neutral	$14.14M	0.57	1.32%	―	-15.44%	-94.04%
NAII	48 Neutral	$29.34M	-2.37	-15.93%	―	18.19%	-35.22%
LSF	48 Neutral	$28.96M	-15.80	-14.63%	―	17.73%	-34.71%
FAMI	42 Neutral	$7.51M	-0.14	-3.22%	―	-49.19%	-394.71%
HCWC	40 Underperform	$5.47M	―	―	―	―	―

Bon Natural Life Corporate Events

Bon Natural Life Secures $12 Million Deal with Qingshengyuan for Kombucha Products

On December 5, 2025, Bon Natural Life Limited announced a strategic collaboration with Shaanxi Qingshengyuan Health Industry Co., Ltd., marking a significant expansion in the functional health product market in China. This agreement, valued at $12 million over 24 months, allows Qingshengyuan to market and distribute BON’s kombucha-inspired tea pigment products across Greater China. The partnership is expected to enhance BON’s market presence and support the development of its tea-pigment product portfolio, aligning with the increasing consumer interest in natural ingredients and health benefits.

The most recent analyst rating on (BON) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.

Bon Natural Life Enters $26M Agreement for Tea Pigment Products in China

On September 1, 2025, Bon Natural Life Limited’s subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd, entered into a significant Sales Cooperation Agreement with Beijing Huahai Keyuan Technology Co., Ltd. This agreement, valued at US$26 million, grants Huahai Keyuan the non-exclusive rights to distribute Bon’s second-generation tea pigment digestive health products across China for 36 months. This strategic partnership is expected to enhance Bon’s market presence in the rapidly growing digestive health sector and drive substantial revenue growth. The agreement underscores Bon’s commitment to leveraging its innovative tea pigment technology to expand its footprint in the global health market.

The most recent analyst rating on (BON) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.

Bon Natural Life Appoints New CFO Amid Leadership Changes

Bon Natural Life Limited, a company operating in the high-tech zone of Xi’an, Shaanxi, China, announced a significant change in its financial leadership. On November 11, 2025, Wallace Lee, the Chief Financial Officer, resigned effective November 14, 2025, with no disagreements reported regarding company operations. Ma Xin, who previously held leadership roles in various companies, was appointed as the new CFO effective November 12, 2025. This leadership transition is expected to bring new strategic insights to the company’s financial operations.

The most recent analyst rating on (BON) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.